Low incidence of CNS relapse with cranial radiotherapy and intrathecal methotrexate in acute lymphoblastic leukemia

Indian Pediatr. 1996 Jul;33(7):556-60.

Abstract

Objectives: To assess the incidence of isolated central nervous system (CNS) relapses in patients of acute lymphoblastic leukemia (ALL) treated with a protocol containing cranial irradiation and intrathecal methotrexate as CNS directed therapy.

Design: Prospective non randomized study.

Setting: Department of Medical Oncology, Tata Memorial Hospital.

Subjects: 623 children of ALL on MCP 841.

Methods: CNS relapse was diagnosed, if upon examination of the CSF, more than 50 cells/microliter were observed, or a count of 5 cells which were unequivocally lymphoblasts.

Results: The incidence of isolated CNS relapse was 1.75% with the use of this treatment. Age, sex, white blood cell count, platelet count, lactic dehydrogenase and immunophenotyping were not significantly related to isolated CNS relapse.

Conclusion: A low incidence of isolated CNS relapse demonstrates the adequacy of the presymptomatic CNS therapy.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Central Nervous System / pathology*
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Cranial Irradiation*
  • Disease-Free Survival
  • Female
  • Humans
  • Leukemic Infiltration / prevention & control*
  • Male
  • Methotrexate / therapeutic use*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / cerebrospinal fluid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*

Substances

  • Antimetabolites, Antineoplastic
  • Methotrexate